AGEN vs. OYST, STRO, PSTX, ADAP, ATHA, MNKD, INVA, OPK, IRWD, and LXRX
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Oyster Point Pharma (OYST), Sutro Biopharma (STRO), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Athira Pharma (ATHA), MannKind (MNKD), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "medical" sector.
Oyster Point Pharma (NASDAQ:OYST) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
Agenus received 434 more outperform votes than Oyster Point Pharma when rated by MarketBeat users. Likewise, 70.14% of users gave Agenus an outperform vote while only 47.69% of users gave Oyster Point Pharma an outperform vote.
In the previous week, Agenus had 8 more articles in the media than Oyster Point Pharma. MarketBeat recorded 11 mentions for Agenus and 3 mentions for Oyster Point Pharma. Oyster Point Pharma's average media sentiment score of 0.46 beat Agenus' score of 0.00 indicating that Agenus is being referred to more favorably in the news media.
Oyster Point Pharma has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Oyster Point Pharma has higher earnings, but lower revenue than Agenus. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Agenus has a net margin of -154.88% compared to Agenus' net margin of -901.99%. Oyster Point Pharma's return on equity of 0.00% beat Agenus' return on equity.
Agenus has a consensus price target of $70.00, indicating a potential upside of 365.74%. Given Oyster Point Pharma's higher probable upside, analysts clearly believe Agenus is more favorable than Oyster Point Pharma.
96.7% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 17.9% of Oyster Point Pharma shares are owned by insiders. Comparatively, 4.6% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Agenus beats Oyster Point Pharma on 11 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
